Cardinal Health has launched the Kendall SCD SmartFlow device in the US, the latest in the company’s series of compression systems to mitigate the risk of venous thromboembolism events (VTE) including deep vein thrombosis (DVT).
The new system offers intermittent pneumatic compression (IPC), an approach past research has found is a superior means of improving blood flow versus rapid inflation devices, to prevent VTE while also addressing pain and swelling related to venous stasis.
With a gradient and circumferential sleeve design (CSD), the system is intended to move more blood per hour than uniform compression. According to Cardinal, the CSD allows therapy to be applied regardless of sleeve and tubing position, while the sleeve’s gradient pressure pattern helps to further maximise blood flow.
Kendall SCD comes equipped with vascular refill detection (VRD) technology which reevaluates each patient's refill time at regular intervals and can automatically adjust for changes in body position, with the overall aim being to ensure individualised patient compression cycles to move blood from the lower extremities as quickly as the veins refill. It also features Patient Sensing Technology (PST), which automatically detects if compression therapy is being applied; if not, the tech will activate an alert if the system’s sleeves are improperly affixed to a patient’s leg.
Steve Marshall, senior vice president of Cardinal Health’s global product marketing division, commented: "We're proud to introduce the reimagined Kendall SCD device to our customers for consistent, effective and reliable compression therapy, providing clinicians with efficiencies so they can focus more of their time on direct patient care.
"We're happy to offer an easy-to-use device that now has the indication to treat pain and swelling, which can be common and debilitating symptoms for patients with insufficient blood flow."
Kendall SCD SmartFlow will be available internationally from early 2025.
Cardinal's move to bolster its compression system portfolio follows the recent signing of definitive agreements to acquire a 71% stake in gastroenterology (GI) management services organisation (MSO) GI Alliance for approximately $2.8bn, and a roughly $1.1bn deal to acquire diabetic medical supply provider Advanced Diabetes Supply Group (ADSG).
According to GlobalData analysis, the global clot management devices market was valued at around $2.23bn in 2023 and is forecast to reach a valuation of around $3.11bn by 2033.
A GlobalData report released in April 2024 indicated that there were 71 clot management devices in active stages of development globally.
In related blood clot news, researchers at the University of British Columbia (UBC) recently shared their newly developed ‘coating’ for blood-contacting medical devices to reduce the risks of blood clots and bleeding.
